Merck KGaA Agrees to Acquire SpringWorks for $3.9 Billion
Merck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read moreMerck KGaA is moving forward with the acquisition of SpringWorks Therapeutics, confirming a definitive agreement at $47 per share in
Read moreLexicon Pharmaceuticals announced an exclusive worldwide licensing agreement with Novo Nordisk for LX9851, a first-in-class oral non-incretin therapy in development for
Read moreIn a significant move to expand its oncology portfolio, Taiho Pharmaceutical Co., Ltd. has entered a definitive agreement to fully
Read moreAmerican multinational pharma company Incyte and AI-focused biotech Genesis Therapeutics have announced a strategic collaboration to leverage artificial intelligence for
Read moreVariant Bio, a leading genomics-driven drug discovery company, announced today it is entering a new, multi-year research collaboration with pharmaceutical
Read moreInsitro, a leading AI-driven drug discovery and development company, has entered into three strategic agreements with Eli Lilly and Company
Read moreAI firm Generate:Biomedicines announced on Tuesday that it has secured a $1B+ collaboration with Novartis to advance AI-driven protein therapeutics.
Read moreSangamo Therapeutics Enters License Agreement with Genentech to Develop Genomic Medicines for Neurodegenerative Diseases Sangamo Therapeutics, Inc., a leader in
Read moreTakeda has secured an exclusive global option and license agreement for AC Immune’s promising active immunotherapy targeting amyloid beta for
Read moreThe Hamburg headquartered publicly listed drug discovery and development company Evotec and Variant Bio, a US-based biotech company leveraging the
Read more